CytomX Therapeutics (CTMX) announced that the first patient has been dosed with CX-801 in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, in the ongoing Phase 1 dose escalation study evaluating safety and initial clinical activity in patients with metastatic melanoma. CytomX is conducting a focused Phase 1 dose escalation study of CX-801 in metastatic melanoma. The combination arm of the study evaluating CX-801 in combination with KEYTRUDA has been initiated following successful the clearance of the first three CX-801 monotherapy dose escalation cohorts.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- Biotech Alert: Searches spiking for these stocks today
- Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
- CytomX Therapeutics price target raised to $5 from $2.50 at Piper Sandler
- Promising Clinical Data and Safety Profile Lead to Buy Rating for CytomX Therapeutics’ CX-2051
- CytomX Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue